Humacyte (HUMA) Gross Margin (2025 - 2026)
Humacyte (HUMA) posted quarterly Gross Margin of 311.72% for Q1 2026, down 38328.0% year-over-year from N/an in Q1 2025, and up 83.1% quarter-over-quarter from 1844.75% in Q4 2025.
Humacyte (HUMA) Gross Margin (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Gross Margin for 2 consecutive years, with 311.72% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 38328.0% year-over-year to 311.72%; the TTM figure through Mar 2026 stood at 475.05% (down 54662.0% YoY), while the FY2025 annual figure was 376.05%, changed N/A from the prior year.
- Gross Margin improved to 311.72% in Q1 2026 per HUMA's latest filing, from 1844.75% in the prior quarter.
- Across five years, Gross Margin topped out at 71.57% in Q1 2025 and bottomed at 1844.75% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -203.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -203.20% |
| Mar 31, 2026 | -311.72% |
| Dec 31, 2025 | -1,844.75% |
| Sep 30, 2025 | 65.47% |
| Jun 30, 2025 | 29.24% |
| Mar 31, 2025 | 71.57% |